The PV carriers in Lynch syndrome genes and BRCA1/BRCA2 could benefit from treatment with immune checkpoint (PD-1/PD-L1 inhibitors) and PARP (PARPi) inhibitors, respectively [9,10]. The gene discussed is PARP1; the disease is acquired polycythemia vera.